We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the amended filing, the city claims the Sacklers knew about the risks associated with the drug by the summer of 1999, leading members of the family to conspire to downplay the danger. Read More
Insulin costs nearly doubled from 2012 to 2016, even as usage remained stable, according to a new analysis from the Health Care Costs Institute (HCCI) — a non-profit funded in part by Aetna, Humana, Kaiser Permanente and UnitedHealthcare. Read More
Both New York City and the Massachusetts Attorney General’s office have set their sights on the family behind Purdue Pharma, alleging the Sackler family continued to push Oxycontin despite detailed knowledge of the overdoses, addiction and deaths the product was causing. Read More
Similarly, Celgene’s blood cancer drug Imnovid/Pomalyst (pomalidomide) saw sales of $513 million in the third quarter, a 23 percent year-over-year increase, and its non-small cell lung cancer treatment Abraxane (paclitaxel) saw revenues increase by 15 percent year-over-year to $288 million. Read More
Bristol-Myers Squibb’s planned acquisition of Celgene this year will dramatically increase BMS’ position in oncology drugs as it absorbs the New Jersey-based company’s portfolio of existing cancer drugs and promising pipeline products. Read More